Evidence Hub

Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis

ClinicalTrials.gov · COMPLETED, 2018

19 participants

Abstract

Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators laboratory recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how 1) blood flow and 2) artery function contribute to exercise capacity in CF.

Conditions: Cystic Fibrosis.

Primary outcome: Acute Study: Percentage Flow-Mediated Dilation (FMD); Baseline Diameter; Peak Diameter; Absolute Change in Diameter; FEV1 (% Predicted); VO2 Peak (Absolute); VO2 Peak (Relative); VO2 Peak (Percent Predicted); VE Peak; RER Peak.

Enrollment: 19 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free